BufferGel

DRUG3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Premier Research

Conditions

HIV InfectionsPregnancy

Phase 1

A Study of BufferGel in Women

CompletedNCT00000927

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Target: 40Updated: 2007-01-09

Phase 2

Effectiveness of BufferGel as a Vaginal Contraceptive

CompletedNCT00065858

Premier ResearchPregnancy

Start: 2001-09-30End: 2005-04-30Target: 975Updated: 2016-08-19

BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women

CompletedNCT00074425

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2005-01-31End: 2008-09-30Updated: 2021-11-08

Related Papers

HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women

Sexually Transmitted Infections2014-06-0432 citations

Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial.

2007-09-0151 citations